Trilostane in advanced breast cancer.

Article Details

Citation

Copy to clipboard

Puddefoot JR, Barker S, Vinson GP

Trilostane in advanced breast cancer.

Expert Opin Pharmacother. 2006 Dec;7(17):2413-9.

PubMed ID

17109615 [ View in PubMed

]

Abstract

Antiestrogens, principally tamoxifen, and aromatase inhibitors have been used as the first- and second-line therapy in patients with advanced postmenopausal breast cancer for many years. However, some patients acquire resistance to these treatments and, at present, further endocrine treatment is achieved by merely substituting the current medication with a different antiestrogen or aromatase inhibitor. Trilostane offers an alternative endocrine treatment due to its unique mode of action. It is an allosteric modulator of the estrogen receptor and targets both the estrogen- and growth factor-dependent pathways through which estradiol stimulates cell proliferation. In clinical trials, trilostane has been shown to be an effective treatment for breast cancer in patients who have relapsed after receiving treatment with one or more forms of endocrine therapy. Ongoing and future clinical trials are examining the potential for the use of trilostane in premenopausal breast cancer, as well as in other malignancies such as prostate cancer.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Trilostane	Estrogen receptor alpha	Protein	Humans	Yes	Allosteric modulator	Details
Trilostane	Estrogen receptor beta	Protein	Humans	Yes	Allosteric modulator	Details